Promoting Genuine Tobacco Products in Russia

Nov.22.2022
Promoting Genuine Tobacco Products in Russia
Alexei Sinitsyn, deputy chairman of the Economic Policy Committee of the Federation Council, called for the elimination of counterfeit tobacco products.

The First Deputy Chairman of the Economic Policy Committee of the Federation Council of Russia, Alexei Sinitsyn. Photo source: ВМЕСТЕ РФ.


In a news report from Federal Information Channel, Alexei Sinitsyn, the first deputy chairman of the Federal Committee's Economic Policy Committee, pointed out at a roundtable discussion specifically focused on the tobacco industry that counterfeit products must be eliminated from the domestic tobacco market.


According to him, despite various efforts made by the nation, the pace at which Russians quit smoking remains slow. Data from Rosstat (Federal State Statistics Service) shows that over 20% of Russian adults smoke, a figure which has remained unchanged for several years. Increasing prices will only make cigarettes more affordable.


The government's role is to establish regulations that will help to standardize the industry, or at least prevent it from entering a massive grey area. The industry's general issues have been repeatedly discussed in various locations, with the main problem being a significant difference in consumption tax rates between Russia and neighboring EAEU countries. SenatInformSinitsyn stated that the government has taken measures to address this issue, but many sectors of the Russian economy, including tobacco, are experiencing significant changes related to unfriendly countries' sanction policies this year.


According to data from Rosstat, the production of legal cigarettes decreased by over 17% in the first half of this year. Meanwhile, the percentage of counterfeit cigarettes is on the rise. According to data from the Ministry of Industry and Trade, over 12% of cigarettes in the country are now counterfeit, up from 11.5% a year ago. The resulting budget loss is estimated at 70 billion rubles, or roughly 8.2 billion yuan.


Statement:


This article compiles information from a third-party source and is intended for internal industry exchange and learning only.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the contents of the article. The compilation of this article is solely for communication and research within the industry.


Due to limitations in translation ability, the article translation may not fully reflect the original text. Please refer to the original text for accuracy.


2FIRSTS is fully aligned with the Chinese government regarding any domestic, Hong Kong, Macau and Taiwan-related, and foreign statements and positions.


Copyright of compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Iowa Sets November 16 Vape Directory Launch: Unlisted Products Face Sales Ban, Manufacturers $1,000 Daily Fines per Product
Iowa Sets November 16 Vape Directory Launch: Unlisted Products Face Sales Ban, Manufacturers $1,000 Daily Fines per Product
Iowa plans to publish its first vapor products directory on November 16, 2026, after which products not listed will be prohibited from sale or offer for sale in the state. The Department of Revenue expects to begin penalty enforcement on December 17, following an initial 21-business-day period focused on compliance education. Under House File 2677, retailers, distributors and wholesalers selling unlisted products face civil penalties of $300 per product per day, while manufacturers face $1,000 per product per day. Eligibility extends to FDA-authorized products and certain products meeting historical marketing and pending PMTA requirements. The directory program resumed after a federal appeals court vacated a preliminary injunction in July 2026.
Regulations
Nov.05
Wisconsin Vape Directory One Year On: Retailer Reports Four Store Closures and 70% Staff Cuts
Wisconsin Vape Directory One Year On: Retailer Reports Four Store Closures and 70% Staff Cuts
Wisconsin's electronic vaping device directory has been fully enforced for more than a year, and local vape retailers say the reduced range of eligible products has contributed to declining sales, store closures and layoffs. Johnny Vapes owner Ben Hall said he has closed four of seven locations and cut about 70% of his staff. State law bars the sale of vaping devices not listed on the Wisconsin Department of Revenue directory and allows penalties of $1,000 per day for each unlisted device sold or offered for sale. In April 2026, the U.S. Court of Appeals for the Seventh Circuit allowed enforcement of the law to continue.
Regulations
Oct.10
New Zealand's Largest Vape Retailer Shosha Faces Advertising Probe Over Offshore Website and Local Fulfilment
New Zealand's Largest Vape Retailer Shosha Faces Advertising Probe Over Offshore Website and Local Fulfilment
New Zealand's Ministry of Health is reviewing its previous assessment of Shosha Global, an international website associated with vape retailer Shosha, after researchers found that the site displayed vaping products while fulfilling orders to New Zealand addresses. Radio New Zealand reported on November 13 that test purchases arrived within three days and shipping documents showed dispatch from Auckland. The researchers also found a store-stock tool listing only New Zealand locations and social media posts carrying local warning labels and cultural references. Shosha, which operates more than 125 stores in New Zealand, says Shosha Global serves overseas customers through an international partnership established in July 2025. No final regulatory finding against the website has been announced.
Regulations
Nov.17
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
KIWI has launched the Spark 2 and Spark 2 Pro refillable pod systems in Germany at official prices of €18 and €29, respectively. Spark 2 uses an 800mAh removable lithium-ion battery in a pen-style body, while Spark 2 Pro features a 1,400mAh removable battery, a box-shaped design and vibration feedback every 20 puffs. Both devices use the same 2ml Spark V2 pods in 0.8Ω and 1.2Ω versions, with AirSync airflow adjustment and a choice between Cotton Tips and conventional Drip Tips. The new pods also remain compatible with the original KIWI Spark.
News
Sep.29 by 2Firsts Perspectives
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23